Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cannovum Cannabis AG (27N0) Fair Value & Analysis

Healthcare · DE · Market cap €1.1M

Price€0.4480
Fair Value€0.2600
Upside-42.0%
Quality80/100
Evidence: Low Range €0.1700 – €0.3300

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Cannovum Cannabis AG (27N0) currently trades at €0.4480, while our model-based Fair Value estimate is €0.2600 — implying the stock looks roughly 42.0% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Cannovum Cannabis AG engages in the manufacturing, wholesaling, and importing of medical cannabis products in Berlin. It also focuses on the import of medical cannabis and medical-scientific education, as well as distribution for facilitated access to cannabis-based therapies. The company was formerly known as Cannovum AG and changed its name to Cannovum Cannabis AG in April 2023. Cannovum Cannabis AG was incorporated in 2018 and is based in Berlin, Germany.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Cannovum Cannabis AG (27N0) undervalued?
As of Jun 25, 2026, our model estimates a fair value of €0.2600 versus a price of €0.4480 — about −42% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 27N0?
Our 21-model fair value for Cannovum Cannabis AG is €0.2600 (as of Jun 25, 2026), built from audited fundamentals. The current price is €0.4480.
What is the quality score of 27N0?
Cannovum Cannabis AG has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.